BioSpace

EMSO 2026: Incyte a ‘firm contender’ in G12D pancreatic cancer race as early candidate shines

In a Phase 1 study, treatment with Incyte's KRAS G12D inhibitor in combination with standard-of-care chemotherapy elicited an 89% confirmed objective response rate in patients with a type of pancreatic ductal adenocarcinoma, leading analysts to draw comparisons with Revolution Medicines’ zoldonrasib.

By BioSpace

1 min read
EMSO 2026: Incyte a ‘firm contender’ in G12D pancreatic cancer race as early candidate shines
AI-generated illustration

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights